Your browser is no longer supported. Please, upgrade your browser.
Settings
ADMS Adamas Pharmaceuticals, Inc. daily Stock Chart
ADMS [NASD]
Adamas Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.10 Insider Own0.40% Shs Outstand29.87M Perf Week-9.08%
Market Cap323.19M Forward P/E- EPS next Y-4.23 Insider Trans-1.09% Shs Float26.27M Perf Month-40.68%
Income-131.50M PEG- EPS next Q-1.38 Inst Own- Short Float25.74% Perf Quarter-50.46%
Sales21.30M P/S15.17 EPS this Y-43.40% Inst Trans-1.86% Short Ratio10.85 Perf Half Y-64.97%
Book/sh4.20 P/B2.58 EPS next Y18.80% ROA-51.70% Target Price42.18 Perf Year-60.92%
Cash/sh7.08 P/C1.53 EPS next 5Y31.40% ROE-106.70% 52W Range10.58 - 44.00 Perf YTD-68.07%
Dividend- P/FCF- EPS past 5Y-41.50% ROI-51.10% 52W High-75.41% Beta1.36
Dividend %- Quick Ratio8.70 Sales past 5Y-56.70% Gross Margin99.00% 52W Low2.27% ATR1.20
Employees164 Current Ratio8.90 Sales Q/Q378150.00% Oper. Margin- RSI (14)29.49 Volatility7.68% 10.24%
OptionableYes Debt/Eq1.01 EPS Q/Q-17.50% Profit Margin- Rel Volume1.12 Prev Close10.84
ShortableYes LT Debt/Eq1.01 EarningsNov 01 AMC Payout- Avg Volume623.53K Price10.82
Recom2.00 SMA20-24.88% SMA50-38.08% SMA200-55.84% Volume696,463 Change-0.18%
Nov-05-18Downgrade Mizuho Buy → Neutral
Oct-05-18Downgrade BofA/Merrill Buy → Neutral
Jul-16-18Initiated H.C. Wainwright Buy $45
Apr-04-18Initiated Leerink Partners Outperform $31
Mar-27-18Initiated BofA/Merrill Buy $39
Nov-29-17Initiated Northland Capital Outperform $70
Nov-08-17Reiterated Noble Financial Buy $33 → $48
Oct-30-17Initiated Evercore ISI Outperform $85
Sep-29-17Resumed Noble Financial Buy $33
Sep-19-17Reiterated Mizuho Buy $26 → $48
Aug-25-17Reiterated JMP Securities Mkt Outperform $29 → $33
Sep-08-16Reiterated Mizuho Buy $22 → $26
Jun-17-16Initiated Noble Financial Buy $25
Jun-16-16Upgrade Mizuho Neutral → Buy $22
May-12-16Reiterated Mizuho Neutral $17 → $16
Apr-28-16Reiterated Mizuho Neutral $14 → $17
Apr-01-16Initiated JMP Securities Mkt Outperform
Jan-19-16Initiated Mizuho Neutral $26
Dec-24-15Reiterated Credit Suisse Outperform $35 → $37
May-05-14Initiated William Blair Outperform $35
Nov-15-18 01:47PM  Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 01:49PM  Adamas to Present at Three November Investor Conferences GlobeNewswire -8.46%
Nov-08-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-18 11:37AM  The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today Motley Fool -29.94%
Nov-01-18 05:52PM  Adamas: 3Q Earnings Snapshot Associated Press
04:01PM  Adamas Reports Third Quarter 2018 Financial Results GlobeNewswire
07:30AM  The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal Benzinga
Oct-26-18 09:00AM  Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018 GlobeNewswire
Oct-24-18 01:11PM  China cutting rare earth output, unnerving global manufacturers Reuters -5.51%
Oct-16-18 09:15AM  Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-12-18 09:00AM  Why Adamas Pharmaceuticals, Inc. Stock Sank in September Motley Fool +5.03%
Oct-08-18 08:30AM  Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Oct-05-18 05:51PM  Adamas Announces New Employment Inducement Grant GlobeNewswire -7.86%
01:59PM  When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)? Simply Wall St.
Oct-04-18 09:00AM  Adamas Announces Publication of Data Demonstrating Dyskinesias Impact on Activities of Daily Living in People with Parkinsons Disease GlobeNewswire
Sep-12-18 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-20-18 08:25AM  Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies Discovering Underlying Factors of Influence GlobeNewswire
Aug-14-18 03:40PM  Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-03-18 07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga
Aug-02-18 07:05PM  Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:59PM  Adamas: 2Q Earnings Snapshot Associated Press
04:01PM  Adamas Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
Aug-01-18 09:00AM  Adamas Pharmaceuticals Launches Dyskinesia Is A Jerk, a Campaign to Raise Awareness and Highlight the Impact of Parkinsons Disease Dyskinesia GlobeNewswire
Jul-26-18 12:05PM  Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018 GlobeNewswire
Jul-09-18 04:39PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Jun-25-18 07:10AM  Free Technical Research on Akorn and Three More Generic Drugs Equities ACCESSWIRE
Jun-22-18 09:12AM  Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day GlobeNewswire
Jun-08-18 05:55PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Jun-07-18 04:30PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
May-24-18 09:05AM  Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics GlobeNewswire
May-17-18 12:02PM  Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-09-18 04:05PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
May-04-18 08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 06:29PM  Adamas: 1Q Earnings Snapshot Associated Press
04:05PM  Adamas Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 03:22PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-26-18 04:05PM  Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018 GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinsons Disease Patients with Dyskinesia ACCESSWIRE
Apr-19-18 11:46AM  Adamas Pharmaceuticals Incs (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry? Simply Wall St. +7.04%
05:30AM  Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Apr-13-18 08:25AM  Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-12-18 05:09PM  Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting GlobeNewswire
Apr-03-18 09:00AM  Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment GlobeNewswire +5.90%
Mar-27-18 12:36PM  Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating Benzinga
10:00AM  Acorda Files Parkinson's Drug Marketing Application in EU Zacks
Mar-20-18 03:26PM  Edited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 09:00AM  Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Mar-14-18 08:25AM  Recent Analysis Shows SMART Global, DBV Technologies S.A, ICON, Adamas Pharmaceuticals, Shenandoah Telecommunications, and Costamare Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-12-18 02:06PM  What Should Investors Know About Adamas Pharmaceuticals Incs (NASDAQ:ADMS) Future? Simply Wall St.
09:51AM  Adamas stock rises 5% on strong launch of Parkinson's drug MarketWatch
09:08AM  Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals Zacks
Mar-06-18 02:35PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-26-18 04:59AM  New Strong Sell Stocks for February 26th Zacks
Feb-25-18 06:29PM  Adamas Pharmaceuticals (ADMS) Q4 2017 Earnings Conference Call Transcript Motley Fool
Feb-23-18 12:35PM  Here's Why Adamas Pharmaceuticals Dropped Today Motley Fool -5.07%
Feb-22-18 04:59PM  Adamas reports 4Q loss Associated Press
12:00PM  Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:07AM  Adamas Pharmaceuticals Earnings Preview Benzinga
Feb-20-18 02:21PM  Why Adamas Pharmaceuticals Fell Today Motley Fool -21.85%
10:07AM  3 Biotech Stocks To Avoid Forbes
Feb-19-18 08:01PM  Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER GlobeNewswire
Feb-13-18 04:01PM  Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018 GlobeNewswire
Feb-09-18 05:26PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-08-18 09:00AM  Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice GlobeNewswire
Feb-07-18 02:09PM  Adamas to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-01-18 04:05PM  Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal GlobeNewswire
Jan-29-18 08:30AM  Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-23-18 08:29PM  Adamas Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jan-22-18 05:50PM  Is Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Worth $38.19 Based On Its Intrinsic Value? Simply Wall St. +6.81%
04:01PM  Adamas Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-11-18 04:18PM  Parkinson's Disease Space Again Under Spotlight This Week Zacks +6.11%
10:54AM  Nektar Notches New Highs As Stock Triples In Two Months Forbes
Jan-10-18 09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-08-18 04:41PM  Adamas Announces U.S. Commercial Launch of GOCOVRI the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinsons Disease Patients GlobeNewswire -5.52%
Dec-27-17 10:56AM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 27, 2017 Capital Cube
Dec-19-17 01:37PM  7 Stocks Ready to Jump Another 30% in 2018 InvestorPlace
Dec-15-17 12:47PM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 15, 2017 Capital Cube
Dec-08-17 04:05PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Dec-04-17 10:50AM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 4, 2017 Capital Cube
Nov-24-17 10:20AM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 24, 2017 Capital Cube
Nov-22-17 03:57PM  9 Stocks Steven Cohen Keeps Buying GuruFocus.com +8.35%
12:42PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-21-17 04:29PM  Acorda Stock Up Despite Phase III Trial on Tozadenant Stops Zacks
Nov-13-17 11:32AM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 13, 2017 Capital Cube
Nov-08-17 04:17PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Nov-07-17 08:17AM  Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-06-17 03:13AM  Edited Transcript of ADMS earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-04-17 03:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-03-17 11:48AM  ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 3, 2017 Capital Cube +6.59%
Nov-02-17 05:26PM  Adamas reports 3Q loss Associated Press
04:01PM  Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results GlobeNewswire
11:50AM  Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 03:17PM  What's Causing Adamas Pharmaceuticals to Spike Higher Today Motley Fool +7.95%
12:16PM  Harry Boxers four stocks to watch this week MarketWatch
09:24AM  Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers TheStreet.com
Oct-31-17 08:08AM  Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : October 31, 2017 Capital Cube
07:30AM  1000% Revenue Growth Should Mean Explosive Upside for AKDS Shareholders ACCESSWIRE
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Went Gregory TChief Executive OfficerNov 07Buy12.983,85049,956199,242Nov 08 06:04 PM
MERRIWEATHER ALFRED GChief Financial OfficerSep 21Sale19.181,66531,93525,460Sep 21 07:12 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerJun 21Sale25.481,00225,53133,794Jun 22 04:50 PM
KING RICHARDChief Operating OfficerJun 21Sale25.482,50163,72548,856Jun 22 04:47 PM
Went Gregory TChief Executive OfficerMar 21Sale25.754,541116,931182,610Mar 22 05:58 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerMar 21Sale25.8998225,42434,128Mar 22 05:56 PM
Prentiss Christopher BChief Accounting OfficerMar 21Sale25.9856714,73117,758Mar 22 05:54 PM
Patni RajivChief Medical OfficerMar 21Sale25.941,25232,47721,515Mar 22 05:51 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerDec 21Sale32.3044014,21228,860Dec 21 04:43 PM